CD274 and non-small cell lung carcinoma: Anti-PD-1/PD-L1 therapies have become the standard therapy in many cancer types, including melanoma, non-small cell lung cancer, colorectal cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, and hepatocellular carcinoma 1.